A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.
- 5-alpha Reductase Inhibitors
- Cardiovascular Diseases
- Double-Blind Method
- Drug-Related Side Effects and Adverse Reactions
- Prostatic Diseases
- Randomized Controlled Trials as Topic